XenoPort (NASDAQ: XNPT) is one of 105 public companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare XenoPort to related businesses based on the strength of its risk, dividends, analyst recommendations, earnings, valuation, institutional ownership and profitability.
Institutional and Insider Ownership
43.2% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 12.0% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This table compares XenoPort and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|XenoPort Competitors||$8.31 billion||$1.11 billion||139.63|
XenoPort’s peers have higher revenue and earnings than XenoPort. XenoPort is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This is a summary of recent recommendations and price targets for XenoPort and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Pharmaceuticals” companies have a potential upside of 20.57%. Given XenoPort’s peers higher probable upside, analysts plainly believe XenoPort has less favorable growth aspects than its peers.
This table compares XenoPort and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
XenoPort peers beat XenoPort on 7 of the 8 factors compared.
XenoPort Company Profile
XenoPort, Inc. is a biopharmaceutical company. The Company is focused on commercializing HORIZANT (gabapentin enacarbil) Extended-Release Tablets in the United States. The Company’s segment is the development and commercialization of product candidates for the treatment of neurological and other disorders. Its development-stage product candidates include XP23829, XP21279 and arbaclofen placarbil. HORIZANT has been approved by the United States Food and Drug Administration for the treatment of moderate-to-severe primary restless legs syndrome in adults and for the management of postherpetic neuralgia in adults. XP23829 is a fumaric acid ester compound and a prodrug of metabolite monomethyl fumarate being developed for the treatment for patients with moderate-to-severe chronic plaque-type psoriasis and/or patients with relapsing forms of multiple sclerosis. XP21279 is a Transported Prodrug of levodopa being developed for the treatment for patients with idiopathic Parkinson’s disease.
Receive News & Ratings for XenoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XenoPort and related companies with MarketBeat.com's FREE daily email newsletter.